SCHEMBL6778874

SCHEMBL6778874

C#C[C@H](CC(=O)O)NC(=O)CNC(=O)c1ccc(Cl)c(NC(=N)N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 7/20 0.51
ITGA2B P08514 6/20 0.51
GPR139 Q6DWJ6 1/20 0.43
HPGD P15428 1/20 0.40
MDM4 O15151 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGAV P06756 1/20 0.40
ITGA5 P08648 1/20 0.40
MDM2 Q00987 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
F7 P08709 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
CASR P41180 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776701 0.87 ITGB3 (0.55) ITGB3ITGA2BGPR139HPGDF7
SCHEMBL6773935 0.83 ITGB3 (0.52) ITGB3ITGA2BGPR139MDM4ITGB1
SCHEMBL6778863 0.83 GPR139 (0.43) GPR139HPGDCA1CA2F7
SCHEMBL6777472 0.83 ITGB3 (0.52) ITGB3ITGA2BGPR139MDM4ITGB1
SCHEMBL6773940 0.83 ITGB3 (0.52) ITGB3ITGA2BGPR139MDM4ITGB1
SCHEMBL6779270 0.82 ITGB3 (0.56) ITGB3ITGA2BGPR139HPGDMDM4
SCHEMBL6774572 0.81 ITGB3 (0.47) ITGB3ITGA2BGPR139ITGB1ITGAV
SCHEMBL7833135 0.78 ITGB3 (0.46) ITGB3ITGA2BGPR139HPGDMDM4
SCHEMBL7348641 0.77 ITGB3 (0.43) ITGB3ITGA2BMDM4ITGB1ITGAV
SCHEMBL6776695 0.77 RAB9A (0.42) GPR139HPGDF7NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP claimed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed